Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome

Neuroendocrinology Letters

Volumn 28, Issue 6, 2007, Pages 807-810

  Shi, Yuhua ^a   Guo, Meng ^a   Yan, Junhao ^a   Sun, Wei ^b   Zhang, Xiaoli ^a,c   Geng, Ling ^a   Xu, Lihong ^a   Chen, Zijiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Body mass index; Insulin resistance; Metabolic characteristics; Oral glucose tolerance test; Polycystic ovary syndrome

Indexed keywords

ESTRADIOL; FOLLITROPIN; LOW DENSITY LIPOPROTEIN; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CHEMOLUMINESCENCE; CHINA; CLINICAL EXAMINATION; CLINICAL FEATURE; DIET RESTRICTION; ENDOCRINE DISEASE; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HOSPITAL PATIENT; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PROLACTIN BLOOD LEVEL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TRANSVAGINAL ECHOGRAPHY;

EID: 37849036611     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Trivax B, Azziz R. Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol. 2007; 50: 168-177
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81: 19-25.
3. Bhathena RK. Therapeutic options in the polycystic ovary syndrome. J Obstet Gynaecol. 2007; 27: 123-129.
4. Harborne L, Fleming R, Lyall H, Sattar N & Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003; 88: 4116-4123.
5. Costello MF & Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertility and Sterility 2003; 79: 1-13.
6. The Rotterdam Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004; 19: 41-47.
7. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
9. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 4426-4433.
10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
11. Harris MI, Hadden WC, Knowler WC & Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534.
12. Kos-Kudła B, Małecka-Mikosz O, Foltyn W, Ostrowska Z, Kudła M, Mazur B. Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levels. Neuro Endocrinol Lett. 2006; 27 (6): 763-767.